Cancer Stem Cell High-Throughput Drug Screening Study

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

November 30, 2021

Study Completion Date

June 30, 2023

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Combination Drug Therapy

"Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"

Trial Locations (1)

98122

Swedish Medical Center, Seattle

All Listed Sponsors
lead

Swedish Medical Center

OTHER

NCT02654964 - Cancer Stem Cell High-Throughput Drug Screening Study | Biotech Hunter | Biotech Hunter